WO2018074865A3 - 유방암 예후 예측용 조성물 및 방법 - Google Patents

유방암 예후 예측용 조성물 및 방법 Download PDF

Info

Publication number
WO2018074865A3
WO2018074865A3 PCT/KR2017/011606 KR2017011606W WO2018074865A3 WO 2018074865 A3 WO2018074865 A3 WO 2018074865A3 KR 2017011606 W KR2017011606 W KR 2017011606W WO 2018074865 A3 WO2018074865 A3 WO 2018074865A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
cancer prognosis
composition
prognosis prediction
prediction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/011606
Other languages
English (en)
French (fr)
Other versions
WO2018074865A2 (ko
Inventor
한원식
이한별
윤성로
김선
권선영
김민수
김효기
한효준
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CELEMICS Inc
SNU R&DB Foundation
Seoul National University Hospital
Original Assignee
CELEMICS Inc
Seoul National University R&DB Foundation
Seoul National University Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CELEMICS Inc, Seoul National University R&DB Foundation, Seoul National University Hospital filed Critical CELEMICS Inc
Publication of WO2018074865A2 publication Critical patent/WO2018074865A2/ko
Publication of WO2018074865A3 publication Critical patent/WO2018074865A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

유방암 예후 예측을 위한 유전자의 발현 수준을 측정하기 위한 제제를 포함하는, 유방암의 예후 예측용 조성물, 상기 조성물을 포함하는 유방암의 예후 예측용 키트, 및 상기 유전자의 발현 수준을 측정하여 유방암의 예후 예측을 위한 정보를 제공하는 방법에 관한 것이다.
PCT/KR2017/011606 2016-10-21 2017-10-19 유방암 예후 예측용 조성물 및 방법 Ceased WO2018074865A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0137278 2016-10-21
KR20160137278 2016-10-21

Publications (2)

Publication Number Publication Date
WO2018074865A2 WO2018074865A2 (ko) 2018-04-26
WO2018074865A3 true WO2018074865A3 (ko) 2018-08-09

Family

ID=62019565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/011606 Ceased WO2018074865A2 (ko) 2016-10-21 2017-10-19 유방암 예후 예측용 조성물 및 방법

Country Status (2)

Country Link
KR (1) KR102001153B1 (ko)
WO (1) WO2018074865A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220249484A1 (en) * 2019-05-17 2022-08-11 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of cancer to ferroptosis-inducing therapies
WO2024106737A1 (ko) * 2022-11-16 2024-05-23 한양대학교 에리카산학협력단 Foxm1 돌연변이체 또는 foxm1 shrna를 포함하는 암 치료용 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035240A1 (en) * 2004-08-10 2010-02-11 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
KR101421326B1 (ko) * 2010-03-30 2014-07-21 서울대학교산학협력단 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
JP2015119716A (ja) * 2008-05-30 2015-07-02 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 乳癌の予後を予測するための遺伝子発現プロフィール
WO2015102208A1 (ko) * 2013-12-30 2015-07-09 가천대학교 산학협력단 줄기세포 배양방법을 이용하여 발굴된 유방암 줄기세포 마커를 이용한 유방암 예후 예측용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
US20140162887A1 (en) * 2011-02-04 2014-06-12 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
CA2874492C (en) * 2012-05-22 2021-10-19 British Columbia Cancer Agency Branch Nano46 genes and methods to predict breast cancer outcome
JP2016519935A (ja) * 2013-05-13 2016-07-11 ナノストリング テクノロジーズ，インコーポレイティド 結節陽性の初期乳癌における再発リスクを予測する方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035240A1 (en) * 2004-08-10 2010-02-11 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
JP2015119716A (ja) * 2008-05-30 2015-07-02 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 乳癌の予後を予測するための遺伝子発現プロフィール
KR101421326B1 (ko) * 2010-03-30 2014-07-21 서울대학교산학협력단 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
WO2015102208A1 (ko) * 2013-12-30 2015-07-09 가천대학교 산학협력단 줄기세포 배양방법을 이용하여 발굴된 유방암 줄기세포 마커를 이용한 유방암 예후 예측용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAERE, S. V. ET AL.: "Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer", CLINICAL CANCER RESEARCH, vol. 14, no. 22, 15 November 2008 (2008-11-15), pages 7452 - 7460, XP055534458 *

Also Published As

Publication number Publication date
WO2018074865A2 (ko) 2018-04-26
KR102001153B1 (ko) 2019-07-18
KR20180044208A (ko) 2018-05-02

Similar Documents

Publication Publication Date Title
ZA202001294B (en) Multispecific antibody
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX390128B (es) Composición para el tratamiento de cáncer con expresión del igf-1r.
EP4279071A3 (en) Novel cannabinoid formulations
PH12018500216B1 (en) Antibody constructs for cd70 and cd3
EP3844509A4 (en) Techniques for analysis of data from smart meters
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
MX2020001278A (es) Sintesis de compuestos de carbamoilpiridona policiclica.
HK1214652A1 (zh) 用於检测胰腺癌的方法和组合物
EP3750907A3 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
EP3180450A4 (en) A method for prognosis of ovarian cancer, patient's stratification
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
EP3690063A3 (en) Diagnosis of lung cancer
MY192513A (en) Compositions and methods related to diagnosis of prostate cancer
EP3245302B8 (en) Mirna-based predictive models for diagnosis and prognosis of prostate cancer
MX382673B (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico.
MX2021000899A (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.
ZA201905895B (en) Kits and methods for preparing pathogen-inactivated platelet compositions
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
EP2988131A4 (en) Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof
EP3498862A3 (en) Differential methylation level of cpg loci that are determinative of a biochemical reoccurrence of prostate cancer
WO2015035403A3 (en) Methods of assessing tumor growth by determining volumetric tumor growth
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
EP4428251A3 (en) Methods of detecting prostate cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17861630

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17861630

Country of ref document: EP

Kind code of ref document: A2